<DOC>
	<DOCNO>NCT00659113</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , S-1 cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving radiation therapy together one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give S-1 cisplatin together radiation therapy work treat patient stage IIA , stage III , stage IVA esophageal cancer remove surgery .</brief_summary>
	<brief_title>S-1 , Cisplatin , Radiation Therapy Treating Patients With Stage IIA , Stage III , Stage IVA Esophageal Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate response rate patient stage IIA-IVA resectable esophageal cancer treat chemoradiotherapy comprise S-1 , cisplatin , radiotherapy . Secondary - To evaluate overall survival patient . - To evaluate progression-free survival patient . - To evaluate toxicity patient . - To correlate initial squamous cell carcinoma antigen C-reactive protein response survival patient . OUTLINE : Patients receive oral S-1 twice weekly , cisplatin IV 2 hour day 1 , undergo radiotherapy 5 day week week 1 2 . Treatment repeat every 3 week 2 course . Tumor tissue sample collect esophagoscopy biopsy brushing analysis initial squamous cell carcinoma antigen C-reactive protein correlation response survival . After completion study treatment , patient follow 6 month .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma esophagus Stage IIAIVA disease Resectable disease Measurable disease , define least 1 measurable lesion RECIST criteria No known brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month ANC ≥ 1,500/uL Hemoglobin ≥ 9.0 g/dL ( transfusion correction allow ) Platelets ≥ 100,000/uL Creatinine &lt; 1.5 mg/dL Total bilirubin &lt; 2 time upper limit normal ( ULN ) ALT/AST &lt; 3 time ULN Fertile patient must use effective contraception Not pregnant nursing Able take oral medication No active peptic ulcer disease No known hypersensitivity study drug No serious uncontrolled systemic intercurrent illness , include follow : Poorly control diabetes Active infection No history significant neurological mental disorder , include seizure dementia No malignancy within past 5 year , except carcinoma situ cervix , nonmelanomatous carcinoma skin No active cardiac disease uncontrolled therapy No myocardial infarction within past 12 month No interstitial lung disease extend fibrosis lung PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy esophageal cancer No prior surgical procedure affect absorption No concurrent flucytosine fluoropyrimidinegroup anticancer drug No concurrent systemic chemotherapy , investigational drug , radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage IIA esophageal cancer</keyword>
	<keyword>stage IIB esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>